MediStress-Voucher for cancer study

Affecting one in three people over the course of their lifetimes, cancer represents a significant burden to healthcare systems around the world, costing the UK economy £11 billion annually. Oxford MediStress, an Oxford University spinout company, has recently developed a new fingerprick blood test that allows the quantitative assessment of a key component of the immune system by evaluating the vitality of white blood cells in a rapid, easy-to-use format. The Company believes this technology holds considerable promise to provide an early indication of cancer, given the way it measures immune function. It also has the potential to become an important new tool with which doctors can monitor cancer progression. In this project we will discuss its potential use in cancer with a cancer specialist and conduct an early-stage proof-of-principle study.